Unknown statusInterventionalNot ApplicableUpdated May 16, 2019
The Role of Tranexamic Acid in Reducing Blood Transfusion Requirements After Cardiopulmonary Bypass in Neonates | NCT01914211 | Trialant
WithdrawnObservationalUpdated Feb 1, 2017
The Role of Tranexamic Acid in Reducing Blood Transfusion Requirements After Cardiopulmonary Bypass in Neonates
ClinicalTrials.gov ID
NCT01914211
Lead Sponsor
Aymen N NaguibOTHER
Overall Status
Withdrawn
Study Type
Observational
Enrollment
0Actual
Last Update Posted
Feb 1, 2017Estimated
Start Date
Jul 2013
Primary Completion Date
Jun 2014Actual
Completion Date
Jun 2014Actual
Brief Summary
This is an observational, prospective study to evaluate the role of tranexamic acid in reducing blood transfusion in neonates undergoing cardiopulmonary bypass.
Congenital Heart Disease
Tranexamic Acid
Acute Normovolemic Hemodilution
Ages Eligible for Study
Child (0-17)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
All neonates undergoing arterial switch or aortic arch procedure utilizing cardiopulmonary bypass (CPB).